Prenatal ethanol exposure causes anxiety-like phenotype and alters synaptic nitric oxide and endocannabinoid signaling in dorsal raphe nucleus of adult male rats

Saida Oubraim1, Ruixiang Wang1, Kathryn Hausknecht1, Martin Kaczocha2, Roh-Yu Shen1,3 and Samir Haj-Dahmane1,3

© The Author(s) 2022

INTRODUCTION
Prenatal ethanol exposure (PE) profoundly alters brain development and causes an array of behavioral and cognitive deficits commonly referred to as Fetal Alcohol Spectrum Disorders (FASDs). Prenatal ethanol exposure is associated with persistent dysfunctions of several neurotransmitter systems, including the serotonin (5-HT) system, which plays a major role in mood regulation and stress homeostasis. While PE is known to disrupt the development of the 5-HT system, the cellular mechanisms by which it alters the function of dorsal raphe nucleus (DRn) 5-HT neurons and their synaptic inputs remain unknown. Here, we used a second-trimester binge-drinking pattern PE (two daily gavages of 15% w/v ethanol at 3 g/kg, 5–6 h apart) during gestational days 8–20 and measured anxiety-like behaviors of adult male rats using the elevated plus (EPM) and zero (ZM) mazes. We also employed ex-vivo electrophysiological and pharmacological approaches to unravel the mechanisms by which PE alters the excitability and synaptic transmission onto DRn 5-HT neurons. We found that PE enhanced anxiety-like behaviors in adult male rats and induced a persistent activation of DRn 5-HT neurons. The PE-induced activation of DRn 5-HT neurons was largely mediated by potentiation of DRn glutamate synapses, which was caused by activation of the nitrergic system and impaired endocannabinoid signaling. As such, the present study reveals “push-pull” effects of PE on nitrergic and eCB signaling, respectively, which mediate the enhanced activity of DRn 5-HT neurons and could contribute to anxiety-like behaviors observed in animal model of FASD.

MATERIALS AND METHODS
Animal use
All experiments and procedures used in this study were approved by the University at Buffalo Animal Care and Use Committee in accordance with the National Institutes of Health Guideline for the Care and Use of Laboratory Animals. Animal breeding and PE treatment were performed as previously described [27]. The electrophysiological, behavioral and

1Department of Pharmacology and Toxicology, State University of New York, 1021 Main Street, Buffalo, NY 14203, USA. 2Department of Anesthesiology, Stony Brook University, Stony Brook, NY 11794, USA. 3University at Buffalo Neuroscience Program, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, 1021 Main Street, Buffalo, NY 14203, USA. 4email: sh38@buffalo.edu

Received: 31 May 2022 Revised: 21 September 2022 Accepted: 27 September 2022 Published online: 10 October 2022
biochemical studies were conducted in distinct cohorts of control and PE male rats. To mitigate the potential litter effects, rats from different litters (2 rats/litter) were used for each experiments.

Behavioral testing
Male rats (8–10 weeks) underwent two different behavioral tests: Elevated plus maze and zero maze as described previously [27]. The plus maze videos were manually coded and zero maze videos were analyzed with the ANY-maze 6.3 software (Stoelting Co., Wood Dale, IL, USA).

Brain slice electrophysiology
Brain slices containing the DRn were obtained from control and PE rat brains (8 to 10 weeks) as previously described [28]. Following recovery at room temperature for at least 1 h, slices were transferred to a recording chamber (Warner Instruments, Hamden, CT, USA) mounted on a fixed upright microscope and continuously perfused (2 to 3 ml/min) with artificial cerebrospinal fluid (ACSF) of the following composition (in mM): 119 NaCl; 2.5 KCl; 2.5 CaCl₂; 1.3 MgSO₄; 1 NaH₂PO₄; 26.2 NaHCO₃; 11 glucose and continuously bubbled with a mixture of 95% O₂/5% CO₂ at 30 ± 1°C. Somatic cell-attached and whole-cell recordings were performed from dorsal medial (dmDRn) and ventral medial (vmDRn) subdivisions of the DRn using potassium-glucuronate based intracellular solution (in mM): 120 potassium gluconate; 10 KCl; 10 Na₂-phosphocreatine; 10 HEPES, 1 MgCl₂, 1 EGTA, 2 Na₂-ATP, and 0.25 Na-GTP; pH 7.3; osmolality 280–290 mOsm/kg. Serotonin neurons were identified by their unique electrical properties, including slow firing activity, large after-hyperpolarization and 5-HT₁A receptor-induced membrane hyperpolarization [28, 29]. Excitatory postsynaptic currents (EPSCs) were evoked by single square-pulses (duration = 100–200 μs) delivered at 0.1 Hz. To access paired-pulse ratio (PPR), a pair of EPSCs were evoked with an inter-stimulus interval of 50 ms. The intensity of the stimulus was adjusted to access paired-pulse ratio (PPR), a pair of EPSCs were evoked with an inter-stimulus interval of 50 ms. The stimulus intensity was adjusted to access paired-pulse ratio (PPR), a pair of EPSCs were evoked with an inter-stimulus interval of 50 ms.

RESULTS
Prenatal ethanol exposure causes anxiety-like behaviors in adult rats
The impact of PE on anxiety-like behaviors was tested in the elevated plus maze (EPM) and zero maze tests (ZM). In the EPM test, compared to control, PE rats spent less time in open arms (control: 12.24 ± 1.7 s; PE: 6.63 ± 1.45 s; Fig. 1A1), and more time in closed arms (control: 18.05 ± 1.79 s; PE: 24.6 ± 1.85 s; Fig. 1A2), with no significant difference in open arms (control: 19.0 ± 3.08; PE: 17.00 ± 1.87; Fig. 1A3), and closed arms entries (control: 10.75 ± 2.87; PE: 10.75 ± 0.75; Fig. 1A4), indicating that PE increases anxiety-like behaviors without altering locomotor activity. In ZM test, no differences in open quadrant time were observed (control: 81.74 ± 6.17 s, n = 20; PE: 78.22 ± 7.45 s; Fig. 1B1), and more time on quadrants they were initially on, reluctance to venture toward farther quadrants, as shown by the representative tracking plots (Fig. 1B2). Collectively, these results indicate that PE increases anxiety-like behavior in adult rats.

Prenatal ethanol exposure enhances the electrical activity of putative DRn 5-HT neurons
Serotonin neuron of the DRn are clustered in various groups, including the dmDRn and vmDRn subdivisions, which project extensively to medial prefrontal cortex (mPFC) and central amygdala (CeA), and play a key role in regulating anxiety-like behaviors [32, 33]. Therefore, we examined whether PE alters the function of dmDRn and vmDRn 5-HT neurons. To that end, we first conducted cell-attached recordings, which revealed that in control rats, dmDRn and vmDRn 5-HT neurons were not spontaneously active (0.01 ± 0.005 Hz; Fig. 2A1–A2), which was consistent with previous reports [28, 34]. In contrast, in PE rats, most dmDRn and vmDRn 5-HT neurons exhibited spontaneous firing activity (0.31 ± 0.05 Hz; Fig. 2A3–A4), demonstrating that PE increases the excitability of adult DRn 5-HT neurons. We next assessed the impact of PE on the intrinsic electrical properties DRn 5-HT neurons and found that PE had no effects on cell input resistance (PC: 1.30 ± 0.12 GΩ; PE: 1.05 ± 0.11 GΩ; n = 8; t-test, t (7) = −1.52, p > 0.05), membrane capacitance and evoked firing activity. These results indicate that PE-induced increase in the excitability of DRn 5-HT neurons is not mediated by alterations of their intrinsic electric properties.
Prenatal ethanol exposure potentiates glutamate synapses of DRn 5-HT neurons

The firing activity of DRn 5-HT neurons is tightly regulated by the strength of their excitatory inputs [35, 36]. Consequently, the increased activity of DRn 5-HT neurons in PE rats could be mediated by a potentiation of DRn glutamate synapses. We first tested this possibility by examining whether blockade of glutamatergic transmission can reverse the increased activity of 5-HT neurons in PE rats. We found that administration of DNQX (20 µM) and AP-5 (20 µM), antagonists of α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) and N-methyl-D-aspartate receptor (NMDAR), respectively, significantly reduced the PE-induced activation of 5-HT neurons (PE: 0.37 ± 0.04 Hz; PE+DNQX & AP5: 0.16 ± 0.02 Hz; Fig. 2B1-B2). Such a finding indicates that a persistent potentiation of glutamate release in the DRn. Consistent with this conclusion, we also found that compared to control rats, PE enhanced the average mEPSC frequency (Control: 13.53 ± 1.09 pA; PE: 14.38 ± 1.63 pA; Fig. 3B1), the cumulative distribution (K-S test: p < 0.05, Fig. 3B2), and decay kinetic of mEPSCs (Tau control: 5.12 ± 0.36 ms; Tau PE: 5.59 ± 0.31 ms; Fig. 3C1-C2), indicating that PE did not alter the function of postsynaptic AMPARs. Taken together, these results indicate that the PE-induced increased electrical activity of 5-HT neurons, is in large part, mediated by a persistent potentiation of glutamate release in the DRn.

Prenatal ethanol exposure enhances tonic NO signaling at DRn glutamate synapses

The strength of DRn glutamate synapses is regulated by various signaling molecules, including nitric oxide (NO) and endocannabinoids (eCBs) signaling. We have previously shown that NO and eCBs retrogradely control the strength of DRn glutamate synapses [37, 38]. Thus an increase in NO and eCBs signaling induce
long-term potentiation and depression of glutamate synapses in the DRn, respectively [37–39]. Because PE alters the function of neuronal nitric oxide synthase (nNOS) function [40] and enhances the formation of reactive nitrogen species (RNS), including peroxynitrite (ONOO-) [41, 42], we hypothesized that an enhanced NO signaling could mediate the PE-induced potentiation of DRn glutamate synapses. We first tested this hypothesis by examining whether reducing tonic NO signaling using NOS inhibitors and NO scavengers can reverse the potentiation of glutamate synapses in PE rats. Remarkably, inhibition of NOS with L-NAME (100 µM) significantly reduced the amplitude of eEPSCs only in DRn slices of PE rats (Control: 108.2 ± 1.98 % of baseline; PE: 58.21 ± 5.5 % of baseline; p < 0.05, η²_p = 0.73, PE vs PC; Fig. 4A1). Similarly, bath application of the NO scavenger PTIO (100 µM) significantly reduced the amplitude of eEPSCs in PE, but not control rats (Control: 102.36 ± 7.67 % of baseline; PE: 70.85 ± 5.92 % of baseline; p < 0.05, η²_p = 0.42, PE vs PC; Fig. 4A2). These observations suggest that an increase in tonic NO signaling contributes to the PE-induced potentiation of DRn glutamate synapses. Consistent with this notion, reducing NO function in the DRn with PTIO (100 µM) inhibited the frequency and the amplitude of mEPSCs in PE (PE: 13.53 ± 0.55 Hz; PE + PTIO: 5.85 ± 0.65 Hz; Fig. 4B1–B2), but not in control rats (Control: 5.68 ± 0.41 Hz; Control + PTIO: 5.88 ± 0.78 Hz; Fig. 4C1–C2). Collectively, these results indicate that an enhanced tonic NO signaling mediates the PE-induced potentiation of DRn glutamate synapses.

In principle, if the PE-induced potentiation of DRn glutamate synapses were to be mediated by an enhanced tonic NO...
signaling and persistent activation of soluble guanylate cyclase and protein kinase G (sGC/PKG) signaling cascade, then due to an occlusion effect, direct activation of this signaling pathway should not potentiate eEPSC amplitude in PE rats. We tested this possibility by conducting three independent sets of experiments. First, we examined the effect of NOS activation on the amplitude of eEPSCs in control and PE rats. As expected, we found in control rats, administration of NO donor SNAP (200 µM) potentiated the eEPSC amplitude (143.96 ± 10.90 % of baseline; Fig. 5A1), and increased glutamate release, as indicated by the decrease in PPR (Baseline: 1.21 ± 0.08; SNAP: 1.11 ± 0.08; Fig. 5A2) and CV (Baseline: 0.45 ± 0.04; SNAP: 0.30 ± 0.02; Fig. 5A3). In contrast, administration of SNAP (200 µM) did not alter the eEPSC amplitude in PE rats (100.64 ± 3.91 % of baseline; Fig. 3Prenatal ethanol exposure increases glutamate release in the DRn. A PE decreases both the PPR and CV of EPSCs (A). Representative pairs of EPSC traces (average of 60 consecutive trials) evoked by paired stimuli (50 ms interval) in control (left trace) and in PE rats (right trace). (A2) Summary plot of the PPR magnitude of EPSCs obtained in control (○, n = 31, N = 11 from 5 litters) and in PE rats (▲, n = 31, N = 11 from 5 litters, independent-samples t-test: p < 0.001). A3 Summary plot of the CV of EPSCs in control (○, n = 32, N = 11 from 5 litters) and PE rats (▲, n = 32, N = 11 from 5 litters, Mann-Whitney test: p < 0.001). B PE increases the frequency, but not the amplitude of mEPSCs. B1 Representative current traces recorded from control (upper traces) and PE rats (lower traces). B2 Scatter plots of the average mEPSC frequency recorded in control (○, n = 18, N = 6 from 3 litters) and PE rats (▲, n = 18, N = 6 from 3 litters, independent-samples t-tests: p < 0.001). B3 Cumulative distribution of mEPSC frequency obtained in control (○) and PE rats (▲) (n = 18, N = 6 from 3 litters, K-S test: p < 0.05). B4 Scatter plots of the average mEPSC amplitude recorded in control (○) and PE rats (▲) (n = 18, N = 6 from 3 litters, independent-samples t-tests: p > 0.05). B5 Cumulative distribution of mEPSC amplitude obtained in control (○) and PE rats (▲) (n = 18, N = 6 from 3 litters, K-S test: p > 0.05). C PE has no effect on the decay kinetic of mEPSCs. C1 Averaged mEPSC traces (100) fitted with single exponential decay function and recorded from control (upper traces) and PE rats (lower traces). Scale bars: 5 pA, 5 ms. C2 Averaged decay time constant of mEPSCs obtained in control (○) and PE rats (▲) (n = 11, N = 5 from 3 litters, independent-samples t-tests: p > 0.05). n = number of cells, N = number of rats.
Next, we examined the effect of NO precursor L-Arg on eEPSC amplitude in control and PE rats and found that L-Arg increased the eEPSC amplitude in control, but not in PE rats (Control: 129.06 ± 4.29 % of baseline; PE: 108.57 ± 7.77 % of baseline; $p < 0.05$, $\eta^2_p = 0.50$, PE vs PC; Fig. 5A1). The L-Arg induced potentiation of eEPSC amplitude was mediated by an increase in glutamate release as indicated by the decrease in PPR (Baseline: 1.24 ± 0.09; L-Arg: 1.11 ± 0.06; $p < 0.05$, $\eta^2_p = 0.78$, PE vs PC; Fig. 5B1).
Fig. 5B2) and CV of eEPSCs (Baseline: 0.36 ± 0.07; L-Arg: 0.28 ± 0.06; Fig. 5B2). Finally, because activation of sGC/PKG pathway mediate NO-induced potentiation of DRn glutamate synapses, we assessed the impact of PE on the sGC/PKG pathway-mediated potentiation of eEPSC amplitude. We found that only in control rats, activation of sGC with A350619 (100 µM) enhanced the eEPSC amplitude (Control: 162.68 ± 11.86 % of baseline; PE: 90.40 ± 5.41 % of baseline; \( p < 0.05, \eta^2_P = 0.68, \text{PE vs PC}; \text{Fig. 5C}). Similarly, activation of PKG with 8pCPT-cGMP (100 µM), potentiated the amplitude of eEPSCs only in control rats (Control: 156.23 ± 5.41 % of baseline; \( p < 0.05, \eta^2_P = 0.88, \text{PE vs PC}; \text{Fig. 5C}). Together these results support the hypothesis that a persistent activation of NO/sGC/PKG signaling pathway contribute to the PE-induced potentiation of DRn glutamate synapses.

Prenatal ethanol impairs tonic eCB signaling at DRn glutamate synapses

Glutamate synapses in the DRn are also controlled by tonic eCB signaling [38]. Manipulations that increase and decrease tonic eCB signaling depress and potentiate the strength of these synapses, respectively [38]. Thus, it is possible that an impaired eCB signaling in PE rats could also contribute to the potentiation of DRn glutamate synapses. We examined this possibility by assessing the effects of PE on tonic eCB signaling measured by the blockade of CB1R-induced potentiation of EPSC amplitude [38]. Consistent with a previous report [38], in control rats, blockade of CB1Rs with AM 251 (3 µM) potentiated the eEPSC amplitude and increased glutamate release (163.81 ± 2.87 % of baseline; \( p < 0.05, \eta^2_P = 0.54, \text{PE vs PC}; \text{Fig. 6A})

Translational Psychiatry (2022) 12:440
Prenatal ethanol exposure occludes the potentiation of DRn glutamate synapses induced by activation of NO/sGC/PKG pathway. A. The potentiation of EPSCs amplitude induced by the NOS activator SNAP is blunted in PE rats. Lower graph depicts a time-course summary of the potentiation of EPSC amplitude induced by SNAP (200 µM) in control (n = 13, N = 6 from 3 litters, paired t-test: p < 0.01, vs baseline) and PE rats (n = 11, N = 5 from 3 litters, paired t-test: p > 0.05, vs baseline). Upper panel illustrates representative EPSC traces taken before (1) and during SNAP application (2). Scale bars: 50 pA, 10 ms. (A1 - A2) Summary graphs of the effect of SNAP (100 µM) on PPR (n = 11, N = 5 from 3 litters, paired t-test: p < 0.001, vs control) and CV (n = 11, N = 5 from 3 litters, paired t-test: p < 0.01) in control rats. Note that the SNAP-induced potentiation of EPSC amplitude in control rats is associated with reduction of both PPR and CV. (B) PE blocks the potentiation of EPSC amplitude induced by the NO precursor L-Arg. Lower panel illustrates a time-course summary of the potentiation of EPSC amplitude induced by L-Arg (100 µM) in control (n = 6, N = 4 from 2 litters, paired t-test: p < 0.01, vs baseline) and PE (n = 8, N = 4 from 2 litters, paired t-test: p > 0.05, vs baseline). Upper graph depicts superimposed sample EPSC traces collected before (1) and during L-Arg application (2). Scale bars: 50 pA, 20 ms. (B1 - B2) Summary graphs of the effect of L-Arg (100 µM) on PPR (n = 7, N = 4 from 2 litters, paired t-test: p > 0.05, vs control) and CV (n = 6, N = 0 from 2 litters, paired t-test: p < 0.01) in control rats. Note that the L-Arg-induced potentiation of EPSC amplitude in control rats is associated with a significant decrease in PPR and CV. (C) PE blocks the potentiation of EPSC amplitude induced by sGC activator. Lower panel is a time-course of the effect of sGC activator A350619 (100 µM) on the amplitude of EPSCs in control (n = 8, N = 5 from 3 litters, paired t-test: p < 0.001, vs baseline) and PE (n = 11, N = 5 from 3 litters, paired t-test: p > 0.05, vs baseline) rats. Upper graph depicts representative EPSC traces taken before (1) and during A350619 application (2) in control (left traces) and PE rats (right traces). Scale bars: 50 pA, 20 ms. (D) PE blocks the potentiation of EPSCs induced by direct activation of PKG. Lower panel is a time-course summary depicting the effect of PKG activator 8pCPT-cGMP (100 µM) on EPSC amplitude in control (n = 7, N = 4 from 2 litters, paired t-test: p < 0.001, vs baseline) and PE rats (n = 6, N = 4 from 2 litters, paired t-test: p > 0.05, vs baseline). Upper graph depicts representative EPSC traces taken before (1) and during 8pCPT-cGMP application (2) in control (left traces) and PE rats (right traces). Scale bars: 50 pA, 20 ms.

**DISCUSSION**

While clinical and preclinical studies have revealed strong associations between abnormal 5-HT system and anxiety disorders observed in FASD, the mechanisms by which PE alters the function of 5-HT neurons remain unknown. Here, using a rodent model of FASD, we show that PE increases anxiety-like behaviors in adult male rats and persistently activates DRn 5-HT neurons. Importantly, we report that the hyper-serotonergic phenotype of PE rats is mainly mediated by a potentiation of DRn glutamate synapses. Furthermore, we demonstrate that the PE-induced potentiation of these synapses is caused by enhanced nitricergic function and impaired eCB signaling in the DRn. As such, the present study reveals novel cellular mechanisms by which PE alters the function of 5-HT system, which could contribute to the increased anxiety-like behaviors reported in PE rats.

Prenatal ethanol exposure is detrimental to the normal brain development and a major risk factor for mood disorders, including anxiety-like behaviors. Indeed, results from numerous behavioral studies in mice and rats have shown that ethanol exposure during the gestational period equivalent to second and third trimester of human pregnancy alters stress homeostasis [43, 44] and increases anxiety-like behaviors [12, 13, 45]. Consistent with this notion, our results show that PE induces an anxiety-like phenotype in adult male rats. A novel finding of this study is that PE also induces a persistent activation of DRn 5-HT neurons. Because activation and inhibition of these neurons exert anxiogenic and anxiolytic-like effects, respectively [46, 47], it is possible that persistent activation of these neurons could contribute to increased anxiety-like behaviors of PE rats. It is noteworthy that inhibition of these neurons via activation of 5-HT₁₅ receptors [48] reduces anxiety-like behaviors in animal model of FASD [49]. Previous studies have reported that PE also increases anxiety-like behaviors in female rats [11, 48]. However, it remains unknown whether the anxiety phenotype of female PE rats is associated with a persistent activation of DRn 5-HT neurons. Future studies are necessary to determine the effects PE on the excitability of DRn 5-HT neurons of adult female rats.

The present study reveals that the PE-induced persistent activation of DRn 5-HT neurons is mainly mediated by a potentiation of their glutamatergic inputs. Indeed, blockade of ionotropic glutamate receptors reverses the PE-induced activation...
of DRn 5-HT neurons. Furthermore, our results show that PE potentiates DRn glutamate synapses by increasing glutamate release as indicated by the decrease in PPR, and CV of EPSCs as well as by the increase of mEPSCs frequency. Interestingly, similar effects have been reported in other brain areas in rats [12, 50] and mice [49], indicating that an increased glutamatergic synaptic transmission may be a common mechanism by which PE persistently enhances neuronal excitability in the brain.

Although, our results establish that PE potentiates DRn glutamate synapses, it remains unknown whether such a potentiation of DRn glutamatergic inputs mediates the increased anxiety-like behaviors in PE rats. It is noteworthy that previous behavioral studies have shown that activation of lateral habenula (LHb) and medial prefrontal cortex (mPFC)-DRn excitatory circuits enhances stress responses [51] and increases anxiety-like behaviors [52]. In addition, recent optogenetic studies have reported that activation of DRn 5-HT neurons projecting to the bed nucleus of the stria terminalis and central amygdala (CeA) promotes anxiety-like behaviors [53, 54]. However, whether PE persistently alters the function of these neuronal circuits remains to be elucidated. Clearly, future optogenetic and behavioral studies are required to dissect...
Fig. 6 PE impairs tonic eCB signaling at DRn glutamate synapses by downregulating CB1 receptors. A PE abolishes tonic eCB-mediated inhibition of glutamatergic synaptic transmission in the DRn. Lower panel is a summary of the time course of normalized EPSCs illustrating the potentiation of EPSC amplitude induced by CB1 antagonist AM 251 (3 µM) in control (n = 10, N = 5 from 3 litters, paired t-test: p < 0.01, vs baseline) and in PE rats (n = 9, N = 5 from 3 litters, paired t-test: p > 0.05, vs baseline). Upper panel illustrates superimposed averaged EPSC traces collected before (1) and during application (2) of AM 251 (3 µM). Scale bars: 50 pA, 20 ms. (B) PE does not alter the levels of AEA and 2-AG in the DRn. Left panel depicts summary of the average AEA levels in the DRn of control (n = 9, N = 5 from 3 litters, paired t-test: p > 0.05, vs PE). Right panel illustrates a summary of the average 2-AG levels in the DRn of control (n = 9, N = 5 from 3 litters) and PE (n = 9, N = 5 from 3 litters, independent t-test: p > 0.05, vs PE). (C) PE blocks the inhibition of EPSC amplitude induced by the CB1R agonist win 55,212-2. Lower graph is a time course summary of the effects of Win 55,212-2 (10 µM) on EPSC amplitude in control (n = 11, N = 6 from 3 litters, paired t-test: p < 0.05, vs baseline) and PE rats (n = 8, N = 5 from 3 litters, paired t-test: p > 0.05, vs baseline). (D) PE reduces the mRNA levels of CB1R in the DRn (independent t-test: p < 0.05, control vs PE). (E) In control rats, persistent blockade of CB1R enhances tonic NO signaling as observed in PE rats. Lower graph is time course summary of the effect of NO scavenger PTIO (100 µM) on the amplitude of EPSCs obtained in DRn slices pre-incubated without (n = 9, N = 4 from 2 litters, paired t-test: p > 0.05, vs baseline) and with AM 251 (3 µM) (n = 9, N = 5 from 3 litters, paired t-test: p < 0.001, vs baseline) in control rats. Upper graph is representative EPSCs traces taken before (1) and during PTIO application (2) in without (left traces) and with AM 251 (right traces) pre-incubation. Scale bars: 50 pA, 20 ms. (F) In PE rats, persistent blockade of CB1R does not alter the depression of EPSC amplitude induced by NO scavenger PTIO. Lower panel is a summary of the time course of the depression of EPSCs induced by PTIO (100 µM) in DRn slices pre-incubated without (n = 9, N = 5 from 3 litters, paired t-test: p < 0.001, vs baseline) and with AM 251 (3 µM) (n = 8, N = 4 from 2 litters, paired t-test: p < 0.001, vs baseline) in PE rats. Upper graph is representative EPSCs traces taken before (1) and during PTIO application (2) in slices pre-incubated without (left traces) and with AM 251 (right traces), respectively. Scale bars: 100 pA, 25 ms. n = number of cells, N = number of rats.

the precise excitatory circuit(s) and DRn 5-HT subgroups encoding anxiety-like behaviors in PE rats.

PE is known to increase glutamate release in other brain areas [12, 55, 56], but the mechanisms underlying this effect are unknown. Here, we report that PE potentiates glutamate release in the DRn via an increase in nitricergic and deficit in eCB signaling. Several lines of evidence support this conclusion. First, in PE, but not in control rats, inhibition of NOS or administration of NO scavengers profoundly inhibits DRn glutamate synapses. Second, the PE-induced increase in glutamate release is reversed by NO scavengers. Finally, PE occludes the potentiation of glutamate synapses induced by activation of sGC/PKG signaling cascade. The conclusion that PE potentiates glutamate synapses via enhanced NO signaling is consistent with previous findings that PE increases the expression and activity of nNOS in several brain areas [57, 58]. Given that the nitricergic system plays an ubiquitous role in controlling synaptic transmission and plasticity throughout the brain [37, 59, 60], it is conceivable that an enhanced NO signaling may mediate the effects of PE on glutamate synapses in other brain areas, though future studies are required to test this notion.

In the brain, at low concentration, NO exerts a rapid regulation of synaptic transmission and plasticity via activation of sGC/PKG signaling cascade [61, 62]. NO can also modulate cellular signaling through proteins S-nitrosylation (SNO), a post-translational protein modification (PTM), in which nitrosogroup (-NO) is incorporated into cysteine thiols to form S-nitrosothiols [63, 64]. This later mechanism is believed to mediate the long-term effects of NO on various aspects of neuronal signaling, including maintenance of synaptic plasticity [65, 66]. While our results show that PE potentiates DRn glutamate synapses via activation of NO/sGC/PKG pathways, they do not exclude the possibility that the persistent effect of PE on glutamate release may involve SNO-mediated mechanisms. Interestingly, previous studies have shown that the increase in NO production induces the s-nitrosylation of membrane proteins controlling synaptic vesicles exocytosis, such as syntaxin [67, 68]. The SNO of syntaxin has been shown to mediate the persistent increase in neurotransmitter release observed in animal model of neurodevelopmental disorders, such autism spectrum disorders (ASD) [69]. However, whether such a mechanism is also involved in FASD remains to be determined. Future proteomic studies are necessary to determine whether PE increases the s-nitrosylation of membrane proteins involved in the regulation of synaptic transmission and plasticity in the DRn and other brain areas.

The present study also reveals that PE reduces the function of CB1Rs in the DRn, which mediates, at least in part the potentiation of glutamatergic synaptic transmission onto 5-HT neurons. This finding is consistent with earlier reports that PE alters the expression and function of CB1Rs in several other brain areas [70, 71] and supports the general concept that PE persistently impairs eCB function in the brain. Importantly, a novel finding of the present study is that in control, but not PE rats, pharmacological manipulations that reduce tonic eCB mimic the PE-induced increase in NO signaling. A parsimonious interpretation of these findings is that the PE-induced deficit in eCB function leads to enhanced activity and a persistent increase in NO signaling. This in turn mediates the potentiation of glutamate synapses of DRn 5-HT neurons in PE rats. While it remains unknown whether the altered function of nitricergic and eCB systems mediate the anxiety-like behaviors in PE rats, previous behavioral studies have revealed key role of both systems in regulating anxiety-like behaviors. Thus, pharmacological or genetic manipulations that inhibit or activate nNOS, the main NO synthetic enzyme, exerts anxiolytic-like and anxiogenic-like effect [72–75], respectively. Importantly, an increase in NO signaling in the DRn has been shown to mediate anxiety-like behaviors induced by ethanol withdrawal [76] and stress exposure [77]. Similarly, genetic or pharmacological manipulations that reduce eCB signaling exert anxiogenic-like effects [78–81]. These studies support the possibility that enhanced nitricergic function and impaired eCB signaling could mediate the increased anxiety-like behaviors in PE rats.

Results from previous studies have reported that PE alters the development of DRn 5-HT neurons and reduces the density of 5-HT projections [17, 18]. While the mechanisms underlying these effects are unknown, it is possible that the "push-pull" effects exerted by PE on NO and eCB signaling, respectively may also contribute to the neurodegenerative effects of PE on the 5-HT system. In this context, it is well established that excessive activation of NO signaling enhances the production of reactive nitrogen species (RNS), such as peroxynitrite (ONOO−) and induces oxidative stress, which promotes cell death [82–85]. In contrast, eCB signaling is known to exert neuroprotective and anti-inflammatory effects [86–88]. However, whether a deficit in eCB signaling combined with enhanced nitricergic function contribute to the neurodegenerative effects of PE on the 5-HT system [17, 18] remains to be established. Future anatomical and pharmacological studies are required to directly test this notion.

REFERENCES

1. Riley EP, McGee CL. Fetal Alcohol Spectrum Disorders: An Overview with Emphasis on Changes in Brain and Behavior. Exp Biol Med. 2005;230:357–65.
2. Chokroborty-Hoque A, Alberry B, Singh SM. Exploring the complexity of intellectual disability in fetal alcohol spectrum disorders. Front Pediatr. 2014;2:90.
3. O’Leary C, Leonard H, Bourke J, D’Antoine H, Bartu A, Bower C. Intellectual disability: population-based estimates of the proportion attributable to maternal alcohol use disorder during pregnancy. Dev Med Child Neurol. 2013;55:271–7.

4. Boseck JJ, Davis AS, Cassady JC, Finch WH, Gelder BC. Cognitive and adaptive skill profile differences in children with attention-deficit hyperactivity disorder with and without comorbid fetal alcohol spectrum disorder. Appl Neuropsychol Child. 2018;5:1:23-6.

5. Lewis CE, Thomas KG, Dodge NC, Molteno CD, Meintjes EM, Jacobson JL, et al. Verbal learning and memory impairment in children with fetal alcohol spectrum disorders. Alcohol Clin Exp Res. 2015;39:724–32.

6. Bertrand J. Fetal alcohol spectrum disorders are clearly brain-based. Dev Med Child Neurol. 2016;58:794–5.

7. Green CR, Milic A, Nakuel SM, Stade BC, Rasmussen C, Munoz DP, et al. Executive function deficits in children with fetal alcohol spectrum disorders (FASD) measured using the Cambridge Neuropsychological Tests Automated Battery (CANTAB). J Child Psychol Psychiatry. 2009;50:688–97.

8. Alati R, Al Mamun A, Williams GM, O’Callaghan M, Najman JM, Bor W. In utero alcohol exposure and prediction of alcohol disorders in early adulthood: a birth cohort study. Arch Gen Psychiatry. 2006;63:1099–16.

9. Baer JS, Sampson PD, Barr HM, Conde PP, Streissguth AP. A 21-year longitudinal analysis of the effects of prenatal alcohol exposure on young adult drinking. Arch Gen Psychiatry. 2003;60:377–85.

10. Hellemans KGC, Slivovska JH, Verma P, Weinberg J. Prenatal alcohol exposure: neurodevelopmental outcomes and magnetic resonance imaging volumetry. Biol Psychiatry. 2005;57:1565.}

11. Lam VYY, Raineki C, Wang LY, Chiu M, Lee G, Ellis L, et al. Role of corticosterone in fetal alcohol effects in mice. I: behavioral de...
54. Ren J. Anatomically Defined and Functionally Distinct Dorsal Raphe Serotonin Sub-systems. -37.
55. Delatour LC, Yeh PWL, Yeh HH. Prenatal exposure to ethanol alters synaptic activity in layer V/VI pyramidal neurons of the somatosensory cortex. Cereb Cortex. 2020;30:1735–51.
56. Krawczyk M, Ramani M, Jian J, Florez CM, Mylvaganam S, Brien J, et al. Hippocampal hyperexcitability in fetal alcohol spectrum disorder: Pathological sharp waves and excitatory/inhibitory synaptic imbalance. Exp Neurol. 2016;280:70–9.
57. Dizon MLV, Brown LA, Black SM. Brain nitric oxide synthase levels increase in response to antenatal ethanol exposure. Alcohol Alcohol. 2004;39:101–5.
58. Deng XS, Deitrich RA. Ethanol metabolism and effects: nitric oxide and its interaction. Curr Clin Pharm. 2007;2:145–53.
59. Brenman JE, Bredt DS. Synaptic signaling by nitric oxide. Curr Opin Neurobiol. 1997;7:374–8.
60. Garthwaite J. From synaptically localized to volume transmission by nitric oxide. J Physiol. 2016;594:9–18.
61. El-Husseini AE, Bladen C, Vincent SR. Molecular characterization of a type II cyclic GMP-dependent protein kinase expressed in the rat brain. J Neurochem. 1995;64:2814–7.
62. Francis SH, Busch JL, Corbin JD, Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterase in nitric oxide and cGMP action. Pharmacol Rev. 2010;62:525–63.
63. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol. 2005;6:150–66.
64. Stamler JS, Simon DI, Osborne JA, Mullins ME, Jaraki O, Michel T, et al. S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci USA. 1992;89:444–8.
65. Bradley SA, Steiner JR. Nitric oxide-mediated posttranslational modifications: Impacts on the Synapse. Oxid Med Cell Longev. 2016;2016:5681036.
66. Nakamura T, Prihodko OA, Pire E, Nagar S, Akhtar MW, Oh CK, et al. Aberrant protein S-nitrosylation contributes to the pathophysiology of neurodegenerative diseases. Neurobiol Dis. 2015;84:99–108.
67. Palmer ZJ, Duncan RR, Johnson JR, Lian LY, Mello LV, Booth D, et al. Shank3 mutation in a mouse model of autism leads to changes in the S-nitroso-proteome and affects key proteins involved in vesicle release and synaptic function. Mol Psychiatry. 2020;25:1835–48.
68. Stringer RL, Laufer BI, Kleiber ML, Singh SM. Reduced expression of brain cannabinoid receptor 1 (Cnr1) is coupled with an increased complimentary microRNA (miR-26b) in a mouse model of fetal alcohol spectrum disorder. Cereb Epigenetics. 2013:5:14.
69. Hauskneth K, Shen Y-L, Wang R-X, Haj-Dahmane S, Shen R-Y. Prenatal ethanol exposure persistently alters endocannabinoid signaling and endocannabinoid-mediated excitatory synaptic plasticity in ventral tegmental area dopaminergic neurons. J Neurosci. 2017;37:5798–808.
70. Workman JL, Trainor BC, Finy MS, Nelson RJ. Inhibition of neuronal nitric oxide reduces anxiety-like responses to pair housing. Behav Brain Res. 2007;187:109–15.
71. Zhang J, Huang XY, Ye ML, Luo CX, Wu HY, Hu Y, et al. Neuronal nitric oxide synthase alteration accounts for the role of 5-HT1A receptor in modulating anxiety-related behaviors. J Neurosci. 2010;30:2433–41.
72. Taheri P, Mohammadi F, Nazeri M, Zarei MR, Chamani G, Esfahlani MA, et al. Nitric oxide role in anxiety-like behavior, memory and cognitive impairments in animal model of chronic migraine. Heliyon 2020;6:e05654.
73. Volke V, Köks S, Vasar E, Bourin M, Bradwejn J, Mannisto PT. Inhibition of nitric oxide synthase causes anxiety-like-like behavior in an elevated plus-maze. Neuroups. 1995;6:1413–6.
74. Gonzaga NA, Batistela MR, Padovan D, de Martinis BS, Tirapelli CR, Padovan CM. Ethanol withdrawal induces anxiety-like effects: Role of nitric oxide synthase in the dorsal raphe nucleus of rats. Alcohol 2016;52:1–8.
75. Sun N, You Y, Yang D, Jiang ZX, Xia T, Zhou QG, et al. Neuronal nitric oxide synthase in dorsal raphe nucleus mediates PTSD-like behaviors induced by single-prolonged stress through inhibiting serotonergic neurons activity. Biochem Biophys Res Commun. 2021;585:139–45.
76. Haller J, Bakos N, Srizmov M, Ledent C, Freund TF. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci. 2002;16:1395–8.
77. Uriegui I, Pérez-Rial S, Ledent C, Palomo T, Manzanares J. Impaired action of anxiolytic drugs in mice deficient in cannabinoid CB1 receptors. Neuropharmacology 2004;46:966–73.
78. Austrich-Olivares A, García-Gutiérrez MS, Illescas L, Gasparyan A, Manzanares J. Cannabinoid CB1 Receptor Involvement in the Actions of CBD on Anxiety and Coping Behaviors in Mice. Pharm (Basel). 2022;15:473.
79. Rodgers RJ, Evans PM, Murphy A. Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice. Behav Pharmacol. 2005;16:405–13.
80. Castillo J, Ramón R, Antoni D. "Nitric oxide–related brain damage in acute ischemic stroke." Stroke. 2000;31:852–7.
81. Dawson VL, Dawson TM. Nitric oxide neurotoxicity. J Chem Neuroanat. 1996;10:179–90.
82. Dawson VL, Dawson TM, Bartley DA, Uhl GR, Snyder SH. Mechanisms of nitric-oxide-mediated neurotoxicity in primary brain cultures. J Neurosci. 1993;13:2651–61.
83. Gatto EM, Roboá NA, Carreras MC, Cherávsky A, Rubio A, Satz ML, et al. Over-expression of neuropilin neuronal nitric oxide synthase in Parkinson’s disease. Nitric Oxide. 2004;6:534–9.
84. Basavarajappa BS, Shivakuma J, Joshi V, Subbanna S. Endocannabinoid system in neurodegenerative disorders. J Neurochem. 2017;142:624–48.
85. Mechoulam R, Spatz M, Shohami E. Endocannabinoids and neuroprotection. Sci STKE. 2002;129:re5.
86. Mechoulam R, Panikashvili D, Shohami E. Cannabinoids and brain injury: therapeutic implications. Trends Mol Med. 2002;8:58–61.

ACKNOWLEDGEMENTS
This work was supported by National Institutes of Health (NHI) grant AA026601 (SHD) and AA 026421 (R-YS).

AUTHOR CONTRIBUTIONS
SO performed electrophysiological experiments and wrote the initial draft. KH performed animal treatment. MK performed electrophysiological experiments and wrote the initial draft. RW performed behavioral tests. KH performed animal treatment. MK performed biochemical quantifications. SH-D and SO designed the experiments and performed data analyses. R-YS participated in the experimental and manuscript editing. SH-D wrote the manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Correspondence and requests for materials should be addressed to Samir Haj-Dahmane.

Reprints and permission information is available at http://www.nature.com/ reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article that are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material, is material that is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022